NanoVation Therapeutics Announces Multi-Target Partnership …
VANCOUVER, British Columbia, September 18, 2024--NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced...
NanoVation Therapeutics Announces Multi-Target Partnership …
Sep 18, 2024 · VANCOUVER, British Columbia-- (BUSINESS WIRE)-- NanoVation Therapeutics, a platform company developing innovative technologies to overcome the barriers of nucleic acid delivery, today announced a...
Novo inks $600M NanoVation deal to study genetic drugs ex-liver
Sep 18, 2024 · Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting...
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian …
Sep 18, 2024 · NVO. Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE: NVO) to advance the development of novel genetic medicines targeting...
Novo Nordisk and NanoVation sign $600m deal in rare and …
Sep 19, 2024 · Novo Nordisk has signed a $600m deal with NanoVation to develop genetic medicines for rare and cardiometabolic diseases. Novo has secured a licence to use NanoVation’s long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery targeting cells outside the liver.
NTx News & Events - NanoVation Therapeutics
NanoVation Therapeutics announces multi-target partnership with Novo Nordisk to develop genetic medicines targeting cardiometabolic and rare diseases. September 18, 2024. NTx is eligible to receive up to ~US$600M and royalties in multi-year deal aimed at enabling nucleic acid delivery to cells outside of the liver.
NanoVation Therapeutics Announces Multi-Target Partnership
Sep 18, 2024 · Under the terms of the agreement, Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases, and up to five additional future targets for cardiometabolic and rare diseases.
Novo Nordisk Enters NanoVation Therapeutics Partnership to …
Oct 4, 2024 · Under the agreement, Novo Nordisk and NanoVation will collaborate to develop base-editing therapies for certain rare genetic diseases and cardiometabolic and rare diseases. NanoVation will receive research funding and is eligible to receive up to $600 million in up-front cash and potential milestone payments, as well as tiered royalties on ...
Enabling genetic medicines - NanoVation Therapeutics
News & Events With the emergence of gene therapies, we are at a crucial turning point in human history. In our lifetimes, we will see major diseases become treatable or curable thanks to this new therapeutic approach.
NanoVation Therapeutics Announces Multi-Target ... - Financial Post
Sep 18, 2024 · NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases. NanoVation will receive research funding and is eligible to receive up to approximately US$600 million in up-front cash and potential milestone payments, as well as tiered royalties on future ...